https://camih.med.uni-jena.de/wiki/history/TestBuch2?feed=atomTestBuch2 - Revision history2026-06-21T20:17:36ZRevision history for this page on the wikiMediaWiki 1.43.1https://camih.med.uni-jena.de/camih/index.php?title=TestBuch2&diff=247&oldid=prevCotto at 14:38, 1 February 20242024-02-01T14:38:11Z<p></p>
<p><b>New page</b></p><div>=Reference=<br />
{{#ask:<br />
[[Lichtmann et al. (2018): Results of a Double-Blind, Randomized, Placebo-Controlled Study of Nabiximols Oromucosal Spray as an Adjunctive Therapy in Advanced Cancer Patients with Chronic Uncontrolled Pain. Journal of pain and symptom management]]<br />
|?Title<br />
|?Author<br />
|?Year<br />
|?Journal<br />
|?DOI<br />
|mainlabel=-<br />
|headers=plain<br />
|format=broadtable<br />
|transpose=yes<br />
}}<br />
<br />
=Study Type=<br />
{{#ask:<br />
[[Lichtmann et al. (2018): Results of a Double-Blind, Randomized, Placebo-Controlled Study of Nabiximols Oromucosal Spray as an Adjunctive Therapy in Advanced Cancer Patients with Chronic Uncontrolled Pain. Journal of pain and symptom management]]<br />
| ?Perspective<br />
| ?Centralized<br />
| ?Blinding<br />
| ?Is randomized<br />
| ?Number of arms<br />
| ?Number of included participants<br />
| ?Number of evaluated participants<br />
| ?Is from country<br />
| ?Drop-out<br />
|mainlabel=-<br />
|headers=plain<br />
|format=broadtable<br />
|transpose=yes<br />
}}<br />
<br />
=Participants=<br />
{{#ask:<br />
[[Lichtmann et al. (2018): Results of a Double-Blind, Randomized, Placebo-Controlled Study of Nabiximols Oromucosal Spray as an Adjunctive Therapy in Advanced Cancer Patients with Chronic Uncontrolled Pain. Journal of pain and symptom management]]<br />
| ?Types of cancer<br />
| ?Stage cancer<br />
| ?Comorbidity<br />
| ?Currently in therapy<br />
| ?Current cancer therapy<br />
| ?Was in therapy before<br />
|mainlabel=-<br />
|headers=plain<br />
|format=broadtable<br />
|transpose=yes<br />
}}<br />
<br />
=Arms=<br />
=Risk of Bias Assessments=<br />
{{#ask:<br />
[[Lichtmann et al. (2018): Results of a Double-Blind, Randomized, Placebo-Controlled Study of Nabiximols Oromucosal Spray as an Adjunctive Therapy in Advanced Cancer Patients with Chronic Uncontrolled Pain. Journal of pain and symptom management]]<br />
| ?RoB Methodology<br />
| ?Risk rating<br />
|mainlabel=-<br />
|headers=plain<br />
|format=broadtable<br />
|transpose=yes<br />
}}<br />
=Outcomes=<br />
=Risk of Bias Assessments=<br />
{{#ask:<br />
[[Lichtmann et al. (2018): Results of a Double-Blind, Randomized, Placebo-Controlled Study of Nabiximols Oromucosal Spray as an Adjunctive Therapy in Advanced Cancer Patients with Chronic Uncontrolled Pain. Journal of pain and symptom management]]<br />
| ?RoB Methodology<br />
| ?Risk rating<br />
|mainlabel=-<br />
|headers=plain<br />
|format=broadtable<br />
|transpose=yes<br />
}}<br />
=Risk of Bias Assessments=<br />
{{#ask:<br />
[[Lichtmann et al. (2018): Results of a Double-Blind, Randomized, Placebo-Controlled Study of Nabiximols Oromucosal Spray as an Adjunctive Therapy in Advanced Cancer Patients with Chronic Uncontrolled Pain. Journal of pain and symptom management]]<br />
| ?RoB Methodology<br />
| ?Risk rating<br />
|mainlabel=-<br />
|headers=plain<br />
|format=broadtable<br />
|transpose=yes<br />
}}</div>Cotto